UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 524, 2023

~~Biostax Corp. (Exact name of registrant as specified in charter)~~BIOSTAX CORP

Florida		000-54933		59-3226705
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

(Exact name of registrant as specified in its charter)

2431 Aloma Ave., Suite 124, Winter Park, Florida	32792
Florida	000-54933	59-3226705
(Address of principal executive offices)	(Zip Code)
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

~~888-391-9355~~2431 Aloma ~~(Registrant’s~~Ave, ~~telephone~~Suite ~~number~~124, ~~including~~Winter ~~area~~Park, ~~code)~~FL 32792

~~Immune Therapeutics, Inc.~~ (~~Former~~Address of ~~name~~Principal orExecutive ~~former~~Offices) ~~address,~~(Zip ~~if changed since last report~~Code)

888-391-9355

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: ~~None.~~

~~Indicate by~~Title ~~check~~of ~~mark~~Each ~~whether~~Class ~~the~~Trading ~~registrant~~Symbol(s) isName ~~an emerging growth company as defined in Rule 405~~ of ~~the~~Each ~~Securities~~Exchange ~~Act~~on ofWhich ~~1933~~Registered orCommon ~~Rule~~BTAX ~~12b-2 of~~OTC ~~the Securities Exchange Act of 1934.~~Pink

~~Emerging~~SECTION ~~Growth~~5 ~~Company~~— ☐CORPORATE GOVERNANCE AND MANAGEMENT

~~If an~~Item ~~emerging~~5.02 ~~growth~~Departure ~~company~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Clay Caperton Renyolds as Director On October 24, ~~indicate~~2023 bythe ~~check~~board ~~mark~~of ifdirectors of Biostax Corp, (the ~~registrant~~“Company”) ~~has~~appointed ~~elected~~Ms. ~~not~~Mary Clay Caperton, age 61 to ~~use~~the Board of Directors in accordance with the ~~extended~~bylaws ~~transition~~of ~~period~~the ~~for~~Issuer. ~~complying~~ Ms. Caperton began her career in the Sports Management Industry and then expanded to working with ~~any~~not-for-profit ~~new~~organizations. She was a member of the Steward School Board of Trustees from 2016-2022 and that included her membership on the Advancement, Governance and Executive Committees. Since 2019, she has been a member of the Bon Secours Richmond Foundation Board and its Development Committee; since 2022 she has also been a member of the Riverside School Board of Trustees, where she is the vice chair of the Development & Governance Committees; since 2022 she has been a member of the Trinity Episcopal School Board of Trustees and is the Chair of its Advancement Committee. Ms. Caperton went to Virginia Polytechnic Institute & State University from 1980-1983 and attended Virginia Commonwealth University from 1984-1986 where she earned a B.S. in Sociology & Anthropology. There are no arrangements or ~~revised~~understandings ~~financial~~between ~~accounting~~Ms. ~~standards~~Caperton ~~provided~~and any other persons pursuant to ~~Section~~which ~~13(~~she was selected as a) director. There are no family relationships that exist between Ms. Caperton and any directors or executive officers of the ~~Exchange~~Company. ~~Act~~In addition, there has been no transaction, nor is there any currently proposed transaction between Ms. ☐Caperton and the Company that would require disclosure under Item 404(a) of Regulation S-K.

~~Item~~SECTION ~~5.03.~~8 ~~Amendments~~— toOTHER ~~Articles of Incorporation or Bylaws; Change in Fiscal Years.~~EVENTS

~~On October~~Item 5,8.01 ~~2023,~~Other ~~Immune~~Events. ~~Therapeutics,~~On ~~Inc.~~November ~~d/b/a~~2, 2023 Biostax Corp (the “Company”) ~~filed~~issued a ~~Articles~~press ofrelease ~~Amendment~~announcing to the ~~Articles~~ appointment of ~~Incorporation~~Ms. ~~(“Amendment”)~~Mary ~~with~~Clay ~~the~~Caperton ~~Secretary~~to its Board of ~~State~~Directors. A Copy of the ~~State~~press ofrelease ~~Florda~~is attached to ~~change~~this ~~its~~report ~~corporate~~as ~~name~~Exhibit ~~from~~99.1. ~~Immune Therapeutics,~~The ~~Inc~~press release furnished in this report as Exhibit 99.1 shall not be deemed to ~~Biostax~~be ~~Corp.,~~“filed” ~~effective~~for ~~October~~the 5,purposes ~~2023.~~of ASection ~~copy~~18 of the ~~Amendment~~Securities isExchange ~~attached~~Act asof ~~Exhibit~~1934 ~~3.1~~or ~~hereto~~otherwise ~~and~~subject ~~incorporated by~~to ~~reference~~the liabilities of that section.

InSECTION ~~connection~~9 ~~with~~— ~~the~~FINANCIAL ~~Company’s~~STATEMENTS ~~name~~AND change, the board of directors amended the Company’s bylaws to reflect the corporate name Biostax Corp., also effective on October 5, 2023. No other changes were made to the bylaws. A copy of the Amended and Restated Bylaws reflecting this amendment is attached as Exhibit 3.2 hereto and incorporated by reference.EXHIBITS

~~On October~~Item ~~20,2023~~9.01 ~~FINRA~~Financial ~~approved~~Statements ~~the name change~~ and ~~assigned a new ticker: “BTAX”~~Exhibits. ~~The~~(d) ~~Company’s common stock will continue to trade on the PINK Stock Market~~Exhibits. ~~Outstanding stock certificates for shares of the Company are not affected by the name change; they continue to be valid and need not be exchanged.~~

Item 8.01 Other Events

Exhibit No.		Description of Exhibit

99.1		Press Release Dated November 2, 2023
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)

On Oct 24, 2023 the Company issued a press release announcing the name change approval, the new ticker and its dedication to advancing HIV treatments and international substance abuse. A copy of the press release is attached to this report as Exhibit 99.1. The press release furnished in this report as Exhibit 99.1 shall not be deemed to be “Filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.SIGNATURES

~~Item~~Pursuant ~~9.01.~~to ~~Financial~~the ~~Statements~~requirements ~~and~~of ~~Exhibits~~the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Exhibit No.		Exhibit Description
3.1		Articles of Amendment to the Articles of Incorporation
3.2		Amended and Restated By-laws of Biostax Corp.
99.1		Press Release dated October 24, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

	BISOSTAX CORP

	By	/s/ Noreen Griffin
	Name:	Noreen Griffin
	Title:	Chief Executive Officer

~~SIGNATURE~~Date: November 2, 2023

~~Pursuant~~INDEX toTO ~~the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~EXHIBITS

Date: October 24, 2023	Biostax Corp
Exhibit No.		Description
	By:	/s/ Noreen McGurrin Griffin
99.1		Press Release Dated November 2, 2023
		Noreen McGurrin Griffin
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)
		Chief Executive Officer

Filing Compare · Biostax Corp.